Ikena Oncology
Boston
Massachusetts
United States
About Ikena Oncology
73 articles with Ikena Oncology
-
Scientists from the U.K. may have identified several more environmental causes for cancer after evaluating genetic data of over 12,000 cancer patients from the NHS files.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development
4/13/2022
Ikena Oncology, Inc. today announced the appointment of Jotin Marango, M.D., Ph.D., to Chief Financial Officer (CFO) and Head of Corporate Development.
-
This year’s AACR Annual Meeting is coming to a close, and there has been a wealth of information and data presented. One topic of discussion stood out—mutations.
-
Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
3/17/2022
Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena™”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the fourth quarter and full year ended December 31, 2021.
-
Kurma Partners earned €160 million in the first closing of its Growth Opportunities fund, and Atlas Venture raked in its largest round of funding yet to invest in new biotech firms.
-
Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting
3/7/2022
Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that it will participate in an oral presentation highlighting the company’s novel TEAD inhibitor, IK-930, at the American Association for Cancer Research (AACR) 2022 Annual Meeting.
-
Ikena Oncology to Participate in Cowen 42nd Annual Health Care Conference
3/1/2022
Ikena Oncology, Inc., a targeted oncology company navigating new territory in patient-directed cancer treatment, announced that management will be participating in the Targeted Oncology Panel at the Cowen & Co 42nd Annual Health Care Conference, taking place March 7-9, 2022.
-
BioSpace Movers & Shakers, Jan. 28
1/28/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Ikena Appoints Richard Wooster, Ph.D., to its Board of Directors
1/26/2022
Ikena Oncology, Inc. today announced the appointment of Richard Wooster, Ph.D., to its Board of Directors.
-
Omega raised $650 million, which it plans to invest in life science companies in the U.S. and Europe.
-
Ikena Appoints Michelle Zhang, Ph.D., Industry and Company Veteran, as Chief Scientific Officer
12/8/2021
Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced the internal promotion of Michelle Zhang, Ph.D., to Chief Scientific Officer (CSO), effective as of late November 2021.
-
Clinical Catch-Up: November 8-12
11/15/2021
It was another busy week for clinical trial news. Here’s a look. -
Ikena Oncology Reports Third Quarter 2021 Financial Results and Corporate Update
11/10/2021
Ikena Oncology, Inc., a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, announced financial results for the quarter ended September 30, 2021.
-
Kindness. Respect. Innovation. Only one of those words typically features in biotech mission statements, but at Ikena Oncology, all three are important – and have been from day one.
-
Clinical Catch-Up: November 1-5
11/8/2021
The first week of November was marked by numerous clinical trial announcements. Here’s a look. -
Ikena Oncology to Participate in November 2021 Virtual Investor Conferences
11/4/2021
Ikena Oncology, Inc., a targeted oncology company navigating new territory in patient-directed cancer treatment, announced that management will participate in several virtual investor conferences in November 2021.
-
This week, the U.S. Food and Drug Administration accepted Investigational New Drug Applications for multiple companies, clearing the way for clinical development.
-
Ikena Oncology Announces FDA Acceptance of IND Application of Novel TEAD Inhibitor IK-930
11/2/2021
Ikena Oncology, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to study its TEAD inhibitor candidate, IK-930, for the treatment of cancers harboring genetic mutations in the Hippo signaling pathway.
-
Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cancer Treatment
10/7/2021
Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that the Company will present two virtual posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 7-10, 2021.